Study of Clinical Variables and Serum Anti-RSV Titer Before and After Administration of Polyclonal Immunoglobulin with High-Titer RSV Immunoglobulin

Overview

About this study

The purpose of this study is to assess the effect of administration of polyclonal immunoglobulin with high-titer respiratory syncytial virus (RSV) immunoglobulin (RI-002, ADMA Biologics) in relation to clinical variables,
serum anti-RSV titer and RSV type and palivizumab sensitivity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Hospitalized patients.
  • Confirmed RSV infection.
  • High-risk host (primary immunodeficiency, receiving cancer chemotherapy, stem cell or solid organ transplant recipient).

Exclusion Criteria: 

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

W Charles Huskins, M.D.

Contact us for the latest status

Contact information:

W Charles Huskins M.D.

(507) 255-8464

Huskins.Charles@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20455836

Mayo Clinic Footer